Skip to main content

Table 3 Systemic embolism risk of different lipoprotein (a) levels (mg/dL) in patients with non-valvular atrial fibrillation

From: Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study

Lp(a) Events, n (%) Crude model Model 1 Model 2 Model 3
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Q1 (<  7.1) 14 (0.3) 1.00   1.00   1.00   1.00  
Q2 [7.1, 13.4) 37 (0.9)a 2.68 (1.45, 4.96) 0.002 2.59 (1.40, 4.80) 0.003 2.60 (1.40,4.82) 0.002 2.48 (1.33, 4.61) 0.004
Q3 [13.4, 25.4) 34 (0.8)b 2.45 (1.31, 4.57) 0.005 2.36 (1.26, 4.40) 0.007 2.39 (1.28, 4.47) 0.006 2.38 (1.27, 4.46) 0.007
Q4 (≥ 25.4) 48 (1.2)c 3.48 (1.92, 6.32) <  0.001 3.27 (1.80, 5.95) <  0.001 3.35 (1.84, 6.09) <  0.001 3.38 (1.85, 6.19) <  0.001
P for trend <  0.001   0.001   0.002   0.001   0.001
Log-Lp(a)   2.66 (1.73, 4.08) <  0.001 2.54 (1.65, 3.91) <  0.001 2.59 (1.68, 4.00) <  0.001 2.78 (1.78, 4.36) <  0.001
  1. Abbreviations: Lp(a) Lipoprotein(a), Log log-transformed, OR Odds ratio, 95% CI 95% confidence interval
  2. Model 1: adjusted for sex, age, and ethnicity; Model 2: adjusted for CHA2DS2-VASc score; Model 3: adjusted for ethnicity, CHA2DS2-VASc score, anticoagulants, lipid-lowering medications, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1, apolipoprotein B, and red-cell distribution width
  3. aindicates a significant difference between Q1 and Q2
  4. bindicates a significant difference between Q1 and Q3
  5. cindicates a significant difference between Q1 and Q4